Monday, August 10, 2020
Havana.- Cuban specialists are working on the clinical evaluation of CIGB-300, an antiviral drug that is used to treat COVID-19 patients.
Executives from the BioCubaFarma business group pointed out that so far, the results of the trials of the product are positive.
The drug, designed by the Genetic Engineering and Biotechnology Center (CIGB), was previously used to treat tumors.
Studies began in May to administer CIGB-300 to patients infected with the SARS-CoV-2 coronavirus.
Among the BioCubaFarma companies, the CIGB stands out for its work to create solutions to fight the pandemic, and at the moment, they are developing 16 lines of research related to treatments for Covid-19.